We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KBC:EURONEXT BRUSSELSKBC Group N.V. Analysis

Data as of 2026-03-10 - not real-time

€110.85

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

KBC shares are trading at €110.85, comfortably below the 20‑day (114.02) and 50‑day (115.75) simple moving averages, signaling short‑term momentum weakness, while remaining above the 200‑day average (102.88) which caps downside risk. The RSI at 42.4 and a bearish MACD histogram reinforce a neutral‑to‑bearish technical outlook, with the price perched near the identified support of €105.75 and well beneath the resistance zone around €125.30. Volatility over the past 30 days is elevated at 27.7% but the beta of 0.47 indicates the stock moves less than the broader market, and trading volume is on an increasing trend, suggesting adequate liquidity. Fundamentally, KBC appears undervalued with a trailing P/E of 12.74 versus the industry average of 17.25 and a forward P/E of 10.22, while delivering an attractive dividend yield of 4.71% on a 48% payout ratio, supporting a solid income component. Analyst consensus (17 analysts) rates the stock as a Buy with a mean target price of €121.15, implying roughly 9% upside potential. The “Extreme Greed” sentiment on the Fear & Greed Index further underscores market optimism, yet the modest max drawdown of 18.7% and a stable capital structure keep downside risk limited. Overall, the blend of defensive valuation metrics, strong dividend sustainability, and modest upside makes KBC a compelling candidate for medium‑ to long‑term accumulation despite near‑term technical softness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMAs indicating limited upside
  • Bearish MACD and neutral RSI suggest caution
  • Support level near €105.75 provides downside buffer

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued P/E relative to industry peers
  • Attractive dividend yield with sustainable payout
  • Analyst consensus buy and ~9% upside to target price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Stable earnings growth and solid ROE (~13.6%)
  • Low beta and strong cash position reduce systemic risk
  • Diversified Central‑Eastern European exposure supports future growth

Key Metrics & Analysis

Financial Health

Revenue Growth12.40%
Profit Margin29.92%
P/E Ratio12.7
ROE13.65%
ROA0.93%
P/B Ratio1.7
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI42.4
Support€105.75
Resistance€125.30
MA 20€114.02
MA 50€115.75
MA 200€102.88
MACDBearish
VolumeIncreasing
Fear & Greed Index77.7

Valuation

Target Price€121.15
Upside/Downside9.29%
GradeUndervalued
TypeBlend
Dividend Yield4.71%

Risk Assessment

Beta0.47
Volatility27.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.